Safety and Patient Satisfaction of AbobotulinumtoxinA for Aesthetic Use: A Systematic Review

Cohen, Joel L.; Scuderi, Nicolò

doi:10.1093/asj/sjx010

Cited by 36 publications

(48 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…AbobotulinumtoxinA (Dysport ® , Ipsen Biopharm Ltd., Wrexham, UK; Azzalure ® , Galderma Ltd., Lausanne, Switzerland), a preparation of BoNT-A, has been approved for the treatment of moderate-to-severe GL across Europe and the USA since 2009. Although the short- and long-term safety and effectiveness of abobotulinumtoxinA for the treatment of GL is well established [ 5 – 9 ], a thorough investigation of subject satisfaction over repeat treatment cycles has not been performed [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

Assessment of Subject and Physician Satisfaction after Long-Term Treatment of Glabellar Lines with AbobotulinumtoxinA (Dysport®/Azzalure®): Primary Results of the APPEAL Noninterventional Study

Gubanova

Tabet²,

Bergerova³

et al. 2018

Aesth Plast Surg

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Assessment of Subject and Physician Satisfaction after Long-Term Treatment of Glabellar Lines with AbobotulinumtoxinA (Dysport®/Azzalure®): Primary Results of the APPEAL Noninterventional Study

Gubanova

Tabet²,

Bergerova³

et al. 2018

Aesth Plast Surg

View full text Add to dashboard Cite

show abstract

“…Combinations of BoNTA to correct wrinkles can achieve the same (or better) results compared to an individual treatment approach, potentially in a shorter time frame and convenience to the patient [ 27 , 28 ]. The treatment also results in very high (>90%) patient satisfaction scores [ 28 – 30 ]. Two studies have used a fractional ablative laser to create microscopic columns in the epidermis and dermis that permitted BoNTA molecules to reach the superficial orbicularis oculi in the lower dermis [ 31 , 32 ].…”

Section: Discussionmentioning

confidence: 99%

A Comparative In Vivo Study on Three Treatment Approaches to Applying Topical Botulinum Toxin A for Crow’s Feet

Cao

Yang

Zhu

et al. 2018

BioMed Research International

View full text Add to dashboard Cite

Objective To evaluate the efficacy and safety of three treatment approaches to applying Botulinum Toxin Type A (BoNTA) for crow's Feet. Methods Thirty female subjects with moderate-to-severe crow's feet were included in this comparative in vivo study. They were randomly divided into three groups, including the local intramuscular, intradermal microdroplet injection, and nanomicroneedle delivered with BoNTA therapy group. After one session, evaluations were done at the time points of weeks one, four, and twelve after the treatment. The assessments included subjective satisfaction, blinded clinical assessment, and the biophysical parameters (skin collagen content, elasticity, hydration, and sebum contents). Results For dynamic wrinkles, intramuscular injection and intradermal microdroplets injection were more effective than nanomicroneedles. For static wrinkles, nanomicroneedles and intradermal microdroplets injection were more effective. However, the intramuscular injection had no significant effect on static wrinkles. At one week and four weeks after the treatment, the skin elasticity, collagen content, and hydration of nanomicroneedle group and intradermal microdroplet group increased more significantly than those of the intramuscular injection group; at twelve weeks after the treatment, the skin elasticity, collagen content, and hydration of intradermal microdroplet group were higher than those of other two groups. However we observed no statistically significant difference in sebum content between the three groups before and after the treatment. Conclusion BoNTA delivered through nanomicroneedles and intradermal microdroplets injection can effectively treat crow's feet. This trial is registered with [2016]KY018-01, registered 16 Feb 2016.

show abstract

“…Нарушение техники введения БТА, неправильно выбранная доза/объем/концентрация препарата БТА может привести к появлению нежелательных явлений. Информация о профиле безопасности при проведении инъекции БТА содержится в инструкции по медицинскому применению каждого препарата [42].…”

Section: распространение и диффузия токсинаunclassified

“…В систематическом обзоре 2017 г. J. Cohen [42] были проанализированы профиль безопасности и уровень удовлетворенности пациентов при применении диспорта по эстетическим показаниям. Был проведен скрининг 364 публикаций за период с 2000 по 2016 г., из которых для проведения анализа было выбрано 86.…”

Section: иммуногенностьunclassified

Conversion ratio between different botulinum neuroprotein product in neurological practice

Orlova¹,

Timerbaeva²,

Khatkova³

et al. 2017

Z. nevrol. psikhiatr. im. S.S. Korsakova

View full text Add to dashboard Cite

Despite nearly 30 years of experience in the application of botulinum toxin type A (BTA) in clinical practice, many fundamental questions of therapy remain valid. There are 5 botulinum toxin type A used for neurological indications in the Russian Federation in 2017. They contain different number of active neuroprotein (150 kDa) in a therapeutic dose of the drug that may have a potential impact on the efficacy and duration of action. The current SmPC of each BTA stated that the unit of activity is unique and can not be compared with any other BTA. In scientific publications one can find many details concerning the equivalence doses of onabotulinumtoxin A (botox) and abobotulinumtoxin A (dysport) and the ratio of units varies from 1:1 to 1:11. However, according to clinical guidelines, systematic reviews and high quality research evidence of recent years, the ratio of units of abobotulinumtoxin A (dysport) and onabotulinumtoxin A (botox) is 3(2,5):1. Use of a fixed ratio of units is possible only when switching from one drug to another or in case of limiting access to specific drug. Botulinum toxin type A is the first line of therapy in the treatment of several neurological diseases. The most commonly used drugs of botulinum toxin type A (botox, dysport, xeomin) have a significant evidence base that confirms their efficacy and optimal safety profile. The main difference between botulinum toxin type A is their potential activity of action, i.e., activity units and total therapeutic dose.

show abstract

Safety and Patient Satisfaction of AbobotulinumtoxinA for Aesthetic Use: A Systematic Review

Cited by 36 publications

References 78 publications

Assessment of Subject and Physician Satisfaction after Long-Term Treatment of Glabellar Lines with AbobotulinumtoxinA (Dysport®/Azzalure®): Primary Results of the APPEAL Noninterventional Study

Assessment of Subject and Physician Satisfaction after Long-Term Treatment of Glabellar Lines with AbobotulinumtoxinA (Dysport®/Azzalure®): Primary Results of the APPEAL Noninterventional Study

A Comparative In Vivo Study on Three Treatment Approaches to Applying Topical Botulinum Toxin A for Crow’s Feet

Conversion ratio between different botulinum neuroprotein product in neurological practice

Contact Info

Product

Resources

About